Completed
PHASE3
INTERVENTIONAL
NCT02054897
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes. (SUSTAIN™ 1-Monotherapy).
Interventions
Name:
semaglutide
Type:
DRUG
Description:
Once weekly, administrated subcutaneously (s.c. under the skin)
Name:
placebo
Type:
DRUG
Description:
Once weekly, administrated subcutaneously (s.c. under the skin)
Primary Outcomes
Measure:
Change in HbA1c (Glycosylated Haemoglobin)
TimeFrame:
Week 0, week 30
Description:
Change from baseline (week 0) in HbA1c was evaluated after 30 weeks of treatment. Missing data were imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.
Trial Information
NCT ID
NCT02054897
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025